Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

Treatment patterns for metastatic castration-resitant prostate cancer (mCRPC) have changed substantially. This analysis shows a clinical benefit for subsequent docetaxel therapy among men with mCRPC whose disease progressed after treatment with abiraterone acetate. Older patients were less likely to be treated with subsequent therapy.